Authors: Jade Parker, Editor
Today at our booth
The third day was one of the most days of the conference for the Oncology Central team as we eagerly waited to discover all the data from the plenary session. We have collated our highlights, let us know your thoughts in the comments below or on social media.
Remember you can find us at booth #4040, or follow our Twitter updates @OncologyCentral.
Tomorrow’s key talk to attend
CheckMate 227 study on Monday 4 June, 15:12–15:24 in Hall B1.
Early-stage breast cancer patients could be spared chemotherapy, TAILORx trial shows
Results from the Phase III TAILORx clinical trial have indicated that most women with hormone receptor-positive, HER2-negative, axillary node-negative early-stage breast cancer and a midrange score on a 21-tumor gene expression assay do not need chemotherapy after surgery.
Is surgery necessary for advanced kidney cancer?
Individuals with advanced kidney cancer can avoid a nephrectomy without compromising their survival, according to results from the CARMENA trial.
KEYNOTE-042: pembrolizumab may be more effective than chemo for advanced NSCLC
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
Practice-changing breakthrough made for rare cancer
A novel chemotherapy strategy has improved cure rates for a rare cancer of the muscle tissue, termed rhabdomyosarcoma.
Best of social media #ASCO18
I look forward to presenting results of the global TAILORx trial at the 2018 ASCO Plenary Session on 6/3/18. It is my privilege to do so on behalf of the 30 authors, > 250 investigators, and 10,273 study volunteers. #TAILORx, #bcsm, #ASCO18 , @eaonc, @EinsteinMed, #NCTN, #NCORP
— Joseph Sparano, MD (@jsparano) June 1, 2018
— NEJM (@NEJM) June 3, 2018
— Hope Rugo (@hoperugo) June 3, 2018